Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report

• Päätekijät: Maria d'Apolito (Tekijä), Rocco Spagnuolo (Tekijä), Maria Anna Siciliano (Tekijä), Vito Barbieri (Tekijä), Cristina Cosco (Tekijä), Lucia Fiorillo (Tekijä), Onofrio Cuomo (Tekijä), Valeria Zuccalà (Tekijä), Pierpaolo Correale (Tekijä), Licia Pensabene (Tekijä), Marco Rossi (Tekijä), Patrizia Doldo (Tekijä), Pierfrancesco Tassone (Tekijä), Pierosandro Tagliaferri (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: SAGE Publishing, 2022-01-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Immune checkpoint inhibitors (ICIs) represent an important advance in the adjuvant treatment of patients with high-risk melanoma. Although the safety profile of anti-programmed cell death protein-1 (PD-1) is fairly acceptable, different immune-related adverse events (irAEs) are described. Herein we...